Literature DB >> 11375285

Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications.

J Nojima1, H Kuratsune, E Suehisa, Y Futsukaichi, H Yamanishi, T Machii, Y Iwatani, Y Kanakura.   

Abstract

BACKGROUND: Anti-phospholipid (aPL) antibodies (Abs) frequently found in the plasma of patients with systemic lupus erythematosus (SLE) have been associated with thrombotic complications. Our aim was to clarify the roles in thrombosis of aPL Abs that react with complexes of phospholipids and plasma proteins such as beta(2)-glycoprotein I (beta(2)-GPI), prothrombin, protein C, protein S, and annexin V.
METHODS: We determined the prevalence of aPL Abs to various phospholipid-binding plasma proteins in SLE patients with arterial thrombosis (30 cases), venous thrombosis (19 cases), thrombocytopenia (14 cases), fetal loss (14 cases), and patients without complications (91 cases). The aPL Abs were measured by an ELISA system in which human plasma proteins (beta(2)-GPI, prothrombin, protein C, protein S, and annexin V) were immobilized on gamma-irradiated or plain polystyrene plates.
RESULTS: All types of aPL Abs were frequently observed in the patients with SLE when gamma-irradiated polystyrene plates were used (51 of 168 cases positive for anti-beta(2)-GPI, 94 of 168 cases positive for anti-prothrombin, 36 of 168 cases positive for anti-protein C, 47 of 168 cases positive for anti-protein S, and 50 of 168 cases positive for anti-annexin V), whereas no Abs to these plasma proteins were detected when plain polystyrene plates were used. Multivariate analysis confirmed that both anti-beta(2)-GPI and anti-prothrombin Abs were significant risk factors for arterial thrombosis [odds ratios (ORs), 8.8 and 14.5, respectively; 95% confidence intervals (CIs), 3.2-25 and 1.8-116, respectively] but not for venous thrombosis. The presence of anti-protein S Abs was a significant risk factor for venous thrombosis (OR, 30.4; CI, 3.3-281) but not for arterial thrombosis. The only significant risk factor for fetal loss was the presence of anti-annexin V Abs (OR, 5.9; CI, 1.4-14.8).
CONCLUSIONS: Patients with SLE frequently have some aPL Abs to beta(2)-GPI, prothrombin, protein C, protein S, and annexin V. Thrombotic complications in SLE may depend on the antigenic specificities of these Abs, alone or in combination.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11375285

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  19 in total

Review 1.  Diagnosis of the antiphospholipid syndrome: how far to go?

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

Review 2.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

Review 3.  The IgG and IgM isotypes of anti-annexin A5 antibodies: relevance for primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

4.  Evaluation of the clinical relevance of anti-annexin-A5 antibodies in Chinese patients with antiphospholipid syndrome.

Authors:  Shulan Zhang; Ziyan Wu; Jing Li; Xiaoting Wen; Liubing Li; Wen Zhang; Jiuliang Zhao; Fengchun Zhang; Yongzhe Li
Journal:  Clin Rheumatol       Date:  2016-12-21       Impact factor: 2.980

Review 5.  Recent advances in the diagnosis of antiphospholipid syndrome.

Authors:  Hyun-Sook Chi
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

6.  Annexin A5 and anti-annexin antibodies in patients with systemic lupus erythematosus.

Authors:  Antoni Hrycek; Paweł Cieślik
Journal:  Rheumatol Int       Date:  2011-02-05       Impact factor: 2.631

7.  Annexin A5 polymorphism (-1C-->T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome.

Authors:  B de Laat; R H W M Derksen; I J Mackie; M Roest; S Schoormans; B J Woodhams; P G de Groot; W L van Heerde
Journal:  Ann Rheum Dis       Date:  2006-01-31       Impact factor: 19.103

8.  TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus.

Authors:  Chang-Hee Suh; Brendan Hilliard; Sophia Li; Joan T Merrill; Philip L Cohen
Journal:  Arthritis Res Ther       Date:  2010-07-16       Impact factor: 5.156

9.  Anti-annexin V antibodies in Takayasu's arteritis: prevalence and relationship with disease activity.

Authors:  N K Tripathy; N Sinha; S Nityanand
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

10.  Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases.

Authors:  Hui Zheng; Yi Chen; Wen Ao; Yan Shen; Xiao-wei Chen; Min Dai; Xiao-dong Wang; Yu-cheng Yan; Cheng-de Yang
Journal:  Arthritis Res Ther       Date:  2009-06-22       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.